As someone who’s spent decades helping Texans navigate the ins and outs of health insurance, I keep a close eye on how new medical tests may (or may not) be covered. The current debate over federal coverage for biomarker tests in DCIS—an early form of non-invasive breast cancer—highlights just how complex these decisions can be. While DCIS starts in the milk ducts and doesn’t always behave the same way, this new test looks at tumor biology to estimate a woman’s risk of recurrence and whether radiation would actually make a difference. Supporters believe it can help doctors and patients decide together who truly needs treatment, and who might safely avoid it. The question now is whether these tests offer enough added value over existing tools to justify insurance coverage under the national system. There’s recognition that these innovations matter, but as of now, lab tests like this still fall outside the new accelerated coverage pathway. Another national panel will weigh in on October 13. My job has always been to help you weigh your options and understand what your insurance actually covers. Developments like this show why it’s so important to stay informed and ask questions about what’s included in your plan.
US Debate Over Breast Test Coverage
